A detailed history of Ifp Advisors, Inc transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Ifp Advisors, Inc holds 356 shares of MDGL stock, worth $115,867. This represents 0.0% of its overall portfolio holdings.

Number of Shares
356
Previous 344 3.49%
Holding current value
$115,867
Previous $73,000 49.32%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 04, 2025

BUY
$202.45 - $354.85 $2,429 - $4,258
12 Added 3.49%
356 $109,000
Q3 2024

Feb 04, 2025

BUY
$212.22 - $292.96 $636 - $878
3 Added 0.88%
344 $73,000
Q2 2024

Jul 30, 2024

BUY
$193.33 - $291.99 $65,925 - $99,568
341 New
341 $95,000
Q3 2021

Oct 06, 2021

SELL
$78.35 - $105.02 $78 - $105
-1 Closed
0 $0
Q2 2021

Jul 13, 2021

BUY
$97.2 - $137.59 $97 - $137
1 New
1 $0

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.57B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Ifp Advisors, Inc Portfolio

Follow Ifp Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.